title: Increased prolactin levels during reserpine treatment of hypertensive patients.
abstract: Serum prolactin levels are significantly greater among hypertensive patients receiving reserpine as compared to levels six weeks after discontinuing the treatment (P less than .005). This association between regular, long-term reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine.
mesh_terms: D000735:Androstenedione / Q000097:blood; D003687:Dehydroepiandrosterone / Q000097:blood; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D011388:Prolactin / Q000097:blood*; D012110:Reserpine / Q000494:pharmacology* / Q000627:therapeutic use; D013268:Stimulation, Chemical; D013997:Time Factors
chemical_list: D004970:Estrone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D004958:Estradiol; D012110:Reserpine; D011388:Prolactin; D013006:Growth Hormone